Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes

A double-tracer study

Carolina Solis-Herrera, Curtis L Triplitt, Jose De Jesús Garduno-Garcia, John Adams, Ralph A Defronzo, Eugenio Cersosimo

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

OBJECTIVE-To assess glucose-lowering mechanisms of sitagliptin (S), metformin (M), and the two combined (M+S). RESEARCH DESIGN AND METHODS-We randomized 16 patients with type 2 diabetes mellitus (T2DM) to four 6-week treatments with placebo (P), M, S, and M+S. After each period, subjects received a 6-h meal tolerance test (MTT) with [14C]glucose to calculate glucose kinetics. Fasting plasma glucose (FPG), fasting plasma insulin, C-peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide (GIP) were measured. RESULTS-FPG decreased from P, 160 ±4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3mg/dL. Mean post-MTT plasma glucose decreased from P, 207 ± 5 to M, 191 ± 4; S, 195 ± 4; and M+S, 161 ± 3mg/dL (P < 0.01). The increase inmean post-MTT plasma insulin and in ISR was similar in P,M, and S and slightly greater inM+S. Fasting plasma glucagon was equal (~65-75 pg/mL) with all treatments, but there was a significant drop during the initial 120 min with S 24% and M+S 34%(both P < 0.05) vs. P 17% andM16%. Fasting and mean post-MTT plasma bioactive GLP-1 were higher (P < 0.01) after S andM+S vs.Mand P. Basal endogenous glucose production (EGP) fell from P 2.0 ± 0.1 to S 1.8 ± 0.1 mg/kg · min, M 1.8 ± 0.2 mg/kg · min (both P < 0.05 vs. P), and M+S 1.5 ± 0.1 mg/kg · min (P < 0.01 vs. P). Although the EGP slope of decline was faster in M and M+S vs. S, all had comparable greater post-MTT EGP inhibition vs. P (P < 0.05). CONCLUSIONS-M+S combined produce additive effects to 1) reduce FPG and postmeal plasma glucose, 2) augment GLP-1 secretion and β-cell function, 3) decrease plasma glucagon, and 4) inhibit fasting and postmeal EGP compared with M or S monotherapy.

Original languageEnglish (US)
Pages (from-to)2756-2762
Number of pages7
JournalDiabetes Care
Volume36
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Metformin
Type 2 Diabetes Mellitus
Glucose
Fasting
Glucagon-Like Peptide 1
Meals
Glucagon
Secretory Rate
Insulin
Glucose Tolerance Test
Sitagliptin Phosphate
C-Peptide
Research Design

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes : A double-tracer study. / Solis-Herrera, Carolina; Triplitt, Curtis L; De Jesús Garduno-Garcia, Jose; Adams, John; Defronzo, Ralph A; Cersosimo, Eugenio.

In: Diabetes Care, Vol. 36, No. 9, 09.2013, p. 2756-2762.

Research output: Contribution to journalArticle

Solis-Herrera, Carolina ; Triplitt, Curtis L ; De Jesús Garduno-Garcia, Jose ; Adams, John ; Defronzo, Ralph A ; Cersosimo, Eugenio. / Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes : A double-tracer study. In: Diabetes Care. 2013 ; Vol. 36, No. 9. pp. 2756-2762.
@article{0bab4e9d6f4e43848cbb2499d853d15b,
title = "Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: A double-tracer study",
abstract = "OBJECTIVE-To assess glucose-lowering mechanisms of sitagliptin (S), metformin (M), and the two combined (M+S). RESEARCH DESIGN AND METHODS-We randomized 16 patients with type 2 diabetes mellitus (T2DM) to four 6-week treatments with placebo (P), M, S, and M+S. After each period, subjects received a 6-h meal tolerance test (MTT) with [14C]glucose to calculate glucose kinetics. Fasting plasma glucose (FPG), fasting plasma insulin, C-peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide (GIP) were measured. RESULTS-FPG decreased from P, 160 ±4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3mg/dL. Mean post-MTT plasma glucose decreased from P, 207 ± 5 to M, 191 ± 4; S, 195 ± 4; and M+S, 161 ± 3mg/dL (P < 0.01). The increase inmean post-MTT plasma insulin and in ISR was similar in P,M, and S and slightly greater inM+S. Fasting plasma glucagon was equal (~65-75 pg/mL) with all treatments, but there was a significant drop during the initial 120 min with S 24{\%} and M+S 34{\%}(both P < 0.05) vs. P 17{\%} andM16{\%}. Fasting and mean post-MTT plasma bioactive GLP-1 were higher (P < 0.01) after S andM+S vs.Mand P. Basal endogenous glucose production (EGP) fell from P 2.0 ± 0.1 to S 1.8 ± 0.1 mg/kg · min, M 1.8 ± 0.2 mg/kg · min (both P < 0.05 vs. P), and M+S 1.5 ± 0.1 mg/kg · min (P < 0.01 vs. P). Although the EGP slope of decline was faster in M and M+S vs. S, all had comparable greater post-MTT EGP inhibition vs. P (P < 0.05). CONCLUSIONS-M+S combined produce additive effects to 1) reduce FPG and postmeal plasma glucose, 2) augment GLP-1 secretion and β-cell function, 3) decrease plasma glucagon, and 4) inhibit fasting and postmeal EGP compared with M or S monotherapy.",
author = "Carolina Solis-Herrera and Triplitt, {Curtis L} and {De Jes{\'u}s Garduno-Garcia}, Jose and John Adams and Defronzo, {Ralph A} and Eugenio Cersosimo",
year = "2013",
month = "9",
doi = "10.2337/dc12-2072",
language = "English (US)",
volume = "36",
pages = "2756--2762",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes

T2 - A double-tracer study

AU - Solis-Herrera, Carolina

AU - Triplitt, Curtis L

AU - De Jesús Garduno-Garcia, Jose

AU - Adams, John

AU - Defronzo, Ralph A

AU - Cersosimo, Eugenio

PY - 2013/9

Y1 - 2013/9

N2 - OBJECTIVE-To assess glucose-lowering mechanisms of sitagliptin (S), metformin (M), and the two combined (M+S). RESEARCH DESIGN AND METHODS-We randomized 16 patients with type 2 diabetes mellitus (T2DM) to four 6-week treatments with placebo (P), M, S, and M+S. After each period, subjects received a 6-h meal tolerance test (MTT) with [14C]glucose to calculate glucose kinetics. Fasting plasma glucose (FPG), fasting plasma insulin, C-peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide (GIP) were measured. RESULTS-FPG decreased from P, 160 ±4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3mg/dL. Mean post-MTT plasma glucose decreased from P, 207 ± 5 to M, 191 ± 4; S, 195 ± 4; and M+S, 161 ± 3mg/dL (P < 0.01). The increase inmean post-MTT plasma insulin and in ISR was similar in P,M, and S and slightly greater inM+S. Fasting plasma glucagon was equal (~65-75 pg/mL) with all treatments, but there was a significant drop during the initial 120 min with S 24% and M+S 34%(both P < 0.05) vs. P 17% andM16%. Fasting and mean post-MTT plasma bioactive GLP-1 were higher (P < 0.01) after S andM+S vs.Mand P. Basal endogenous glucose production (EGP) fell from P 2.0 ± 0.1 to S 1.8 ± 0.1 mg/kg · min, M 1.8 ± 0.2 mg/kg · min (both P < 0.05 vs. P), and M+S 1.5 ± 0.1 mg/kg · min (P < 0.01 vs. P). Although the EGP slope of decline was faster in M and M+S vs. S, all had comparable greater post-MTT EGP inhibition vs. P (P < 0.05). CONCLUSIONS-M+S combined produce additive effects to 1) reduce FPG and postmeal plasma glucose, 2) augment GLP-1 secretion and β-cell function, 3) decrease plasma glucagon, and 4) inhibit fasting and postmeal EGP compared with M or S monotherapy.

AB - OBJECTIVE-To assess glucose-lowering mechanisms of sitagliptin (S), metformin (M), and the two combined (M+S). RESEARCH DESIGN AND METHODS-We randomized 16 patients with type 2 diabetes mellitus (T2DM) to four 6-week treatments with placebo (P), M, S, and M+S. After each period, subjects received a 6-h meal tolerance test (MTT) with [14C]glucose to calculate glucose kinetics. Fasting plasma glucose (FPG), fasting plasma insulin, C-peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide (GIP) were measured. RESULTS-FPG decreased from P, 160 ±4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3mg/dL. Mean post-MTT plasma glucose decreased from P, 207 ± 5 to M, 191 ± 4; S, 195 ± 4; and M+S, 161 ± 3mg/dL (P < 0.01). The increase inmean post-MTT plasma insulin and in ISR was similar in P,M, and S and slightly greater inM+S. Fasting plasma glucagon was equal (~65-75 pg/mL) with all treatments, but there was a significant drop during the initial 120 min with S 24% and M+S 34%(both P < 0.05) vs. P 17% andM16%. Fasting and mean post-MTT plasma bioactive GLP-1 were higher (P < 0.01) after S andM+S vs.Mand P. Basal endogenous glucose production (EGP) fell from P 2.0 ± 0.1 to S 1.8 ± 0.1 mg/kg · min, M 1.8 ± 0.2 mg/kg · min (both P < 0.05 vs. P), and M+S 1.5 ± 0.1 mg/kg · min (P < 0.01 vs. P). Although the EGP slope of decline was faster in M and M+S vs. S, all had comparable greater post-MTT EGP inhibition vs. P (P < 0.05). CONCLUSIONS-M+S combined produce additive effects to 1) reduce FPG and postmeal plasma glucose, 2) augment GLP-1 secretion and β-cell function, 3) decrease plasma glucagon, and 4) inhibit fasting and postmeal EGP compared with M or S monotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84891784779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891784779&partnerID=8YFLogxK

U2 - 10.2337/dc12-2072

DO - 10.2337/dc12-2072

M3 - Article

VL - 36

SP - 2756

EP - 2762

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 9

ER -